Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02203773 · ClinicalTrials.gov registry record · Phase 1
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 212
- Enrollment target
NCT02203773 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 212 participants.
The verdict
NCT02203773, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 212 participants
- Enrollment target
Study Summary
This is a Phase 1b, open-label, non-randomized, multicenter study to evaluate the safety and pharmacokinetics of orally administered venetoclax (ABT-199) combined with decitabine or azacitidine and the preliminary efficacy of these combinations. In addition, there is a drug-drug interaction (DDI) sub-study only at a single site, to assess the pharmacokinetics and safety of venetoclax (ABT-199) in combination with posaconazole.
Interventions
- DRUG Azacitidine
- DRUG Decitabine
- DRUG Posaconazole
- DRUG ABT-199
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2014-10-06 |
| Est. Completion | 2022-06-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02203773
The ClinicalTrials.gov registry entry for NCT02203773 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Azacitidine is the first listed.
NCT02203773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02203773 about?
NCT02203773 is a clinical study titled "Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)". This is a Phase 1b, open-label, non-randomized, multicenter study to evaluate the safety and pharmacokinetics of orally administered venetoclax (ABT-199) combined with decitabine or azacitidine and the preliminary efficacy of these combinations. In addition, there is a drug-drug interaction (DDI) su...
What is the current status of trial NCT02203773?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 212 participants. The study started on 2014-10-06. Estimated completion is 2022-06-16.
What interventions are being tested in trial NCT02203773?
The interventions under investigation include: Azacitidine (DRUG), Decitabine (DRUG), Posaconazole (DRUG), ABT-199 (DRUG).
Who is sponsoring clinical trial NCT02203773?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.